Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis

Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation

(2016) Choon-Soo Lee et al.   Scientific Reports

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

(2015) Tadashi Namisaki et al.   JOURNAL OF GASTROENTEROLOGY

Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways

(2015) Rania M. Abdelsalam et al.   JOURNAL OF NEUROCHEMISTRY

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

(2015) Rosa Barreira da Silva et al.   NATURE IMMUNOLOGY

Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis

(2014) Yun-A. Jung et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells

(2014) Christoph Brenner et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses

(2013) D. Anz et al.   DIABETES OBESITY & METABOLISM

Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model

(2013) Yosuke Aihara et al.   HEPATOLOGY RESEARCH

Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats

(2013) Angelo Pietro Femia et al.   INTERNATIONAL JOURNAL OF CANCER

Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis

(2013) Hitoshi Yoshiji et al.   JOURNAL OF GASTROENTEROLOGY

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

(2013) Kosuke Kaji et al.   JOURNAL OF GASTROENTEROLOGY

Paradoxical impairment of angiogenesis, endothelial function and circulating number of endothelial progenitor cells in DPP4-deficient rat after critical limb ischemia

(2013) Cheuk-Kwan Sun et al.   Stem Cell Research & Therapy

Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress

(2012) K. Kaji et al.   CURRENT MEDICINAL CHEMISTRY

DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy

(2012) Markus L. Alter et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats

(2011) Kosuke Kaji et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Impact of Renin-Angiotensin System in Hepatocellular Carcinoma

(2011) H. Yoshiji et al.   CURRENT CANCER DRUG TARGETS

NOX2 is the primary source of angiotensin II-induced superoxide in the macula densa

(2010) Yiling Fu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis

(2010) Herbert Tilg et al.   HEPATOLOGY

Non-alcoholic fatty liver disease: The mist gradually clears

(2008) Nimantha Mark Wilfred de Alwis et al.   JOURNAL OF HEPATOLOGY